Vanguard Group Inc. Boosts Stock Holdings in Sarepta Therapeutics, Inc. $SRPT

Vanguard Group Inc. grew its position in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 9.2% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 11,810,729 shares of the biotechnology company’s stock after buying an additional 993,283 shares during the quarter. Vanguard Group Inc. owned 0.11% of Sarepta Therapeutics worth $254,167,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also recently made changes to their positions in the company. Aberdeen Group plc grew its holdings in shares of Sarepta Therapeutics by 59.6% during the third quarter. Aberdeen Group plc now owns 1,982,764 shares of the biotechnology company’s stock valued at $38,208,000 after buying an additional 740,360 shares during the last quarter. Boxer Capital Management LLC grew its holdings in shares of Sarepta Therapeutics by 900.0% during the third quarter. Boxer Capital Management LLC now owns 250,000 shares of the biotechnology company’s stock valued at $4,818,000 after buying an additional 225,000 shares during the last quarter. Mirador Capital Partners LP purchased a new stake in shares of Sarepta Therapeutics during the fourth quarter valued at approximately $3,012,000. Wealth Enhancement Advisory Services LLC grew its holdings in shares of Sarepta Therapeutics by 143.9% during the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 106,759 shares of the biotechnology company’s stock valued at $2,410,000 after buying an additional 62,981 shares during the last quarter. Finally, Principal Financial Group Inc. grew its holdings in shares of Sarepta Therapeutics by 109.1% during the third quarter. Principal Financial Group Inc. now owns 468,067 shares of the biotechnology company’s stock valued at $9,020,000 after buying an additional 244,181 shares during the last quarter. Hedge funds and other institutional investors own 86.68% of the company’s stock.

Sarepta Therapeutics Stock Down 4.1%

SRPT opened at $19.95 on Friday. The company has a current ratio of 4.63, a quick ratio of 1.48 and a debt-to-equity ratio of 0.56. Sarepta Therapeutics, Inc. has a 1-year low of $10.41 and a 1-year high of $44.14. The company has a market capitalization of $2.11 billion, a PE ratio of -20.78, a PEG ratio of 0.32 and a beta of 0.26. The firm’s 50 day simple moving average is $19.77 and its two-hundred day simple moving average is $20.30.

Sarepta Therapeutics (NASDAQ:SRPT) last released its quarterly earnings results on Wednesday, May 6th. The biotechnology company reported $3.16 earnings per share for the quarter, topping the consensus estimate of $0.98 by $2.18. Sarepta Therapeutics had a negative net margin of 2.94% and a positive return on equity of 7.56%. The business had revenue of $730.80 million for the quarter, compared to the consensus estimate of $474.16 million. During the same period last year, the firm earned ($3.42) earnings per share. The company’s quarterly revenue was down 1.9% on a year-over-year basis. As a group, equities analysts forecast that Sarepta Therapeutics, Inc. will post 2.89 EPS for the current year.

Insiders Place Their Bets

In other Sarepta Therapeutics news, Director Stephen Mayo sold 7,239 shares of the stock in a transaction that occurred on Thursday, March 12th. The shares were sold at an average price of $17.02, for a total value of $123,207.78. Following the transaction, the director directly owned 1,765 shares in the company, valued at approximately $30,040.30. This trade represents a 80.40% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 6.90% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on the stock. Wedbush increased their price objective on shares of Sarepta Therapeutics from $29.00 to $35.00 and gave the company an “outperform” rating in a research report on Thursday, March 26th. Barclays assumed coverage on shares of Sarepta Therapeutics in a research report on Wednesday, January 28th. They set an “equal weight” rating and a $20.00 price objective on the stock. Wells Fargo & Company lowered their price objective on shares of Sarepta Therapeutics from $45.00 to $38.00 and set an “overweight” rating on the stock in a research report on Friday, February 27th. Royal Bank Of Canada increased their price objective on shares of Sarepta Therapeutics from $18.00 to $19.00 and gave the company a “sector perform” rating in a research report on Tuesday, April 7th. Finally, Weiss Ratings upgraded shares of Sarepta Therapeutics from a “sell (d-)” rating to a “sell (d)” rating in a research report on Wednesday, April 22nd. Nine investment analysts have rated the stock with a Buy rating, thirteen have assigned a Hold rating and six have issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $27.71.

Sarepta Therapeutics News Roundup

Here are the key news stories impacting Sarepta Therapeutics this week:

• Positive Sentiment: Wedbush said Sarepta’s commercial portfolio alone could support a higher valuation, suggesting the market may be underappreciating the company’s existing business. Sarepta Therapeutics’ Commercial Portfolio Alone Should Support Higher Valuation, Wedbush Says
• Positive Sentiment: Sarepta’s Q1 results beat estimates on both earnings and revenue, and management maintained its 2026 outlook, reinforcing that the company is still generating solid financial results despite pressure on Elevidys. Sarepta Therapeutics (SRPT) Q1 Earnings and Revenues Top Estimates
• Neutral Sentiment: Analysts remained divided, with J.P. Morgan keeping a Hold rating and Citi reiterating a Sell rating, reflecting uncertainty around pipeline execution and regulatory risk. Safety Overhangs and Regulatory Uncertainty Reinforce Sell Rating and Unchanged $13 Price Target
• Negative Sentiment: Several reports highlighted that Elevidys demand has weakened after a regulatory crackdown, which is the main reason the stock is under pressure even after the earnings beat. SRPT stock plunges 7% after-hours as Elevidys demand slumps — CEO still sees return to growth

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc is a biopharmaceutical company focused on the discovery and development of precision genetic medicines for rare neuromuscular diseases. Headquartered in Cambridge, Massachusetts, Sarepta’s core expertise lies in designing RNA-targeted therapies and gene therapies that address underlying genetic mutations. The company’s mission is to transform the treatment paradigm for patients with Duchenne muscular dystrophy (DMD) and related disorders through innovative modalities.

Sarepta’s commercial products include several exon-skipping therapies approved by the U.S.